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Introduction
Inhibitory antibodies to factor VIII (FVIII) or factor IX (FIX) develop 
in approximately 30% of previously untreated patients with severe 
hemophilia A and in 3–5% of previously untreated patients with 
severe hemophilia B who initiate treatment with coagulation factor 
concentrates [1–4]. The management of patients who develop high-
responding inhibitors (≥5 Bethesda units/mL) frequently includes 
the use of bypassing agents, such as recombinant factor VIIa (rFVIIa; 
NovoSeven®) or Factor Eight Bypassing Activity (FEIBA®) [5]. rFVIIa 
is administered with the aim of providing supraphysiological levels 
of FVIIa to enhance the rate of thrombin generation on thrombin-
activated platelet surfaces in the absence of FVIII or FIX [6]. Although 
highly effective in treating bleeds in hemophilia patients with 
inhibitors, the short half-life of rFVIIa (estimated to be 2.3 hours 
in this population [7]) necessitates intravenous (IV) administration 
every 2–3 hours to achieve hemostasis [7].
Recombinant fusion protein linking recombinant factor VIIa 
with recombinant albumin (rVIIa-FP) is a novel fusion protein that 
has been designed to extend the half-life of rFVIIa with the aim 
of achieving more effective and convenient care for patients with 
hemophilia A or B and inhibitors. The molecule is produced by the 
fusion of “wild-type” rFVIIa to recombinant albumin using a non-
cleavable 31-amino-acid glycine–serine linker and expressed as a 
single moiety by Chinese hamster ovary cells (Figure 1) [8,9]. No 
modification of the FVIIa amino acid sequence is required to produce 
rVIIa-FP and, upon activation, the FVII activity provided by rVIIa-FP 
mirrors that of wild-type rFVIIa [8,9].
Preclinical studies of rVIIa-FP in animal models
The pharmacokinetics (PK) and pharmacodynamics (PD) of 
rVIIa-FP have been evaluated extensively across various animal 
models. In one of the first preclinical studies conducted, wild-type 
rFVIIa, NovoSeven®, rVIIa-FP (all at a dose of 100 μg/kg body weight), 
or plasma-derived human serum albumin (at a dose of 500 mg/kg 
body weight) were administered to CD® rats, with FVII and albumin 
antigen levels measured up to 24 hours postinjection using an 
enzyme-linked immunosorbent assay [9]. In this study, the half-life 
of rVIIa-FP was found to be 6.7-fold longer than that of wild-type 
rFVIIa and 5.8-fold longer than that of NovoSeven® [9]. The recovery 
(i.e. the percentage recovered 5 minutes after injection) of rVIIa-FP 
was 47.1% compared with just 19.5% after NovoSeven® and 34.8% 
after wild-type rFVIIa injection. The combination of an improved 
recovery, reduced clearance, and prolonged half-life with rVIIa-FP 
resulted in an area under the curve that was 9.5-fold and 14.5-fold 
higher with rVIIa-FP than with wild-type rFVIIa and NovoSeven®, 
respectively [9].
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The novel fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) is designed 
to extend the half-life of recombinant factor VIIa (rFVIIa) and improve the care of hemophilia A or B patients 
with inhibitors. Preclinical studies in various animal models have demonstrated markedly improved 
pharmacokinetic and pharmacodynamic properties, as well as prolonged retention in the joint tissues, of 
rVIIa-FP compared with a commercially available rFVIIa (NovoSeven®). A phase I study in healthy volunteers 
– the first study in the PROLONG-7FP program – confirmed that rVIIa-FP has a good tolerability profile in 
doses of up to 1,000 μg/kg and has demonstrated enhanced pharmacodynamic activity relative to rFVIIa. 
The half-life of rVIIa-FP at the highest dose investigated in the study was 8.5 hours, which represents a 3- to 
4-fold half-life extension compared with rFVIIa. Encouraging results from preclinical and phase I studies have 
led to the initiation of clinical studies of rVIIa-FP in patients with congenital hemophilia A or B and inhibitors, 
and in patients with confirmed factor VII deficiency. The results from these studies are awaited with interest 
by clinicians and patients alike.
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Subsequent PK studies comparing single IV doses of rVIIa-FP and 
NovoSeven® in hemophilia A mice, rats, rabbits, and cynomolgus 
monkeys confirmed these initial findings and demonstrated 
enhanced recovery, reduced clearance, and a substantial prolonga-
tion of the rFVIIa half-life after the administration of rVIIa-FP 
compared with NovoSeven® (Figure 2) [10].
The improved PK properties of rVIIa-FP relative to NovoSeven® 
have translated into enhanced PD activity in animal models [10]. 
Studies using thrombin generation assay in hemophilia A mice 
reported prolonged activity and enhanced thrombin generation 
after the administration of equimolar doses of rVIIa-FP compared 
with NovoSeven® [10]. The procoagulant activity of rVIIa-FP was also 
enhanced compared with NovoSeven® in a rabbit model of venous 
thrombosis [10].
The tissue distribution of rVIIa-FP and NovoSeven® has recently 
been studied in rats using quantitative whole-body and knee-joint 
autoradiography [11]. In this study, Sprague–Dawley rats received 
a single IV injection of tritium-labeled rVIIa-FP 10 mg/kg (n=8) 
or NovoSeven® 1.6 mg/kg (n=4) and underwent autoradiography 
for 240 hours or 24 hours, respectively, post-administration. The 
tissue distribution patterns observed for both products were 
similar, with both penetrating well into many tissues, including the 
kidney, bone endosteum, bone marrow, spleen, muscles, liver, and 
skin. NovoSeven® and rVIIa-FP penetrated rapidly into knee-joint 
structures, with the highest concentrations found in the calcified 
cartilage, endosteum, and periosteum. A detailed analysis of the 
knee joint showed high levels of radioactivity within 15 minutes 
of administration of both rVIIa-FP and NovoSeven® (Figure 3). 
However, by 24 hours after administration of NovoSeven®, levels 
were almost undetectable in the knee. In contrast, radioactivity 
was still detectable up to 120 hours after administration of rVIIa-FP, 
indicating markedly prolonged tissue retention [11].
Phase I study of rVIIa-FP in healthy volunteers
A phase I safety and PK study of rVIIa-FP in healthy volunteers 
has also been completed as part of the PROLONG-7FP clinical 
development program [12]. The study was a prospective, double-
blind, placebo-controlled study that enrolled 40 healthy, young (aged 
Fig. 1. Design of the recombinant fusion protein linking recombinant factor VIIa with 
recombinant albumin (rVIIa-FP): designed to extend the half-life of recombinant 
activated factor VII (rFVIIa) and improve patient care.
Fig. 2. Plasma concentration–time profiles of recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) and recombinant activated factor VII 
(rFVIIa; NovoSeven®) in (A) hemophilia A mice, (B) rats, (C) rabbits and (D) cynomolgus monkeys [10]. Data shown are means, except for mice (plasma pool) and monkeys, where 
the curve for each animal is shown. FVII:Ag, factor VII antigen. Reproduced from Zollner S et al. Pharmacological characteristics of a novel, recombinant fusion protein linking 
coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Res 2014; 12: 220–228. CC-BY-NC-ND © 2013 International Society on Thrombosis and Haemostasis.
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18–35 years), male volunteers who had been rigorously screened 
for thrombotic risk factors, including congenital thrombophilia. 
Before the first dose of study medication was administered, and 
throughout the study, all subjects were anticoagulated with a 
daily dose of an oral vitamin K antagonist (warfarin) to achieve a 
prothrombin international normalized ratio (INR) between 2 and 3. 
Once a stable INR had been reached, subjects received a single IV 
injection of rVIIa-FP or placebo (normal saline) administered over 
15 minutes. Blood samples for PK analysis were obtained before 
each injection and up to 120 hours after the start of each injection. 
Subjects were dosed in a staggered manner in five cohorts, with six 
subjects per cohort receiving a single dose of rVIIa-FP (140, 300, 500, 
750, or 1000 μg/kg) and two subjects per treatment arm receiving 
placebo. A safety monitoring board reviewed the data from each 
cohort before the next dose-escalation cohort could enter the study.
rVIIa-FP was well tolerated in this study. There were no serious 
adverse events and no thromboembolic events of any severity 
observed. Only one adverse event was judged to be related to rVIIa-
FP, and that was described as pain and hardening of the vein at the 
injection site. No antidrug antibodies developed during up to 28 days 
of postinfusion monitoring, and there was no evidence of systemic 
activation of coagulation in any subject after the administration of 
rVIIa-FP.
The maximum (Cmax) baseline-corrected mean FVIIa plasma 
activity increased in a dose-proportional manner. Clearance ranged 
from 7.62 to 12.74 mL/hour and the median FVIIa activity-based 
terminal half-life ranged from 6.1 hours (140 μg/kg cohort) to 
9.7 hours (300 μg/kg cohort) after a single dose of rVIIa-FP. At the 
highest dose level investigated (1000 μg/kg), the median terminal 
half-life of rVIIa-FP was 8.5 hours – a 3- to 4-fold half-life extension 
compared with NovoSeven® [12].
An immediate decrease in the prothrombin INR was observed 
after the administration of rVIIa-FP, with a normal INR achieved 
within 60 minutes. By 24 hours postadministration, more than 96% 
of subjects who received rVIIa-FP had maintained an INR <1.5 and 
by 48-hours postdose, more than 50% of these subjects still had an 
INR <1.5, indicating the sustained biological activity of the fusion 
protein. By contrast, in a similar study assessing NovoSeven® in 
doses ranging from 5 to 320 μg/kg [13], more than 50% of subjects 
had an INR >1.5 within 24 hours of dosing.
Conclusions
There are significant unmet needs in the management of 
hemophilia patients with inhibitors, not least of which is the 
need to extend the dosing interval of bypassing agents to simplify 
treatment, improve clinical outcomes, and, potentially, enable the 
use of prophylactic regimens. rVIIa-FP is a novel fusion protein that 
has been developed to meet these needs, offering a prolonged half-
life compared with NovoSeven®, sustained clinical activity, and a 
good tolerability profile. Additional clinical studies in patients with 
hemophilia A or B and inhibitors, and in those with FVII deficiency, 
are now underway, and the results are awaited with interest.
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Fig. 3. Quantitative whole-body autoradiography images of knee-joint tissue obtained 0.25–120 hours (h) after dosing with tritium-labeled (A) recombinant fusion protein linking 
recombinant factor VIIa with recombinant albumin ([3H]-rVIIa-FP) or (B) recombinant activated factor VII (NovoSeven®) ([3H]-rFVIIa) in rats [11]. Reproduced from Herzog E, et al. 
Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): tissue distribution in rats. Thromb Res 2014;134:495-502. CC-BY-NC-ND © 2014 Elsevier Ltd.
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